Foghorn Therapeutics Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $30.9M | $22.6M | $34.2M | $19.2M | $1.3M |
| Operating income | -$86.4M | -$102.7M | -$107.9M | -$117.1M | -$100.7M |
| Operating expenses | $117.3M | $125.3M | $142.1M | $136.4M | $102.1M |
| Cash from operations | -$86.1M | -$100.4M | -$118.1M | $193.6M | -$50.2M |
| Capital expenditure | $50,000 | $906,000 | $1.2M | $1.2M | $3.3M |
| Free cash flow | -$86.1M | -$101.3M | -$119.3M | $192.4M | -$53.6M |
| Impairments | — | — | $0 | $0 | $0 |
| Total assets | $198.1M | $284.0M | $285.9M | $404.9M | $519.8M |
| Total liabilities | $306.6M | $329.5M | $363.1M | $404.8M | $422.9M |
Shares outstanding 58.7M · Free float 90.2%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.